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Impaired Nitric Oxide Mediated 
Vasodilation In The Peripheral 
Circulation In The R6/2 Mouse 
Model Of Huntington’s Disease
Andrew D. Kane, Youguo Niu, Emilio A. Herrera†, A. Jennifer Morton & Dino A. Giussani
Recent evidence shows that the Huntington’s disease (HD) extends beyond the nervous system to 
other sites, including the cardiovascular system. Further, the cardiovascular pathology pre-dates 
neurological decline, however the mechanisms involved remain unclear. We investigated in the R6/2 
mouse model of HD nitric oxide (NO) dependent and independent endothelial mechanisms. Femoral 
artery reactivity was determined by wire myography in wild type (WT) and R6/2 mice at 12 and 16 
weeks of adulthood. WT mice showed increased endothelial relaxation between 12 and 16 weeks 
(Rmax: 72 ± 7% vs. 97 ± 13%, P < 0.05). In contrast, R6/2 mice showed enhanced endothelial relaxation 
already by 12 weeks (Rmax at 12w: 72 ± 7% vs. 94 ± 5%, WT vs. R6/2, P < 0.05) that declined by 16 
weeks compared with WT mice (Rmax at 16w: 97 ± 13% vs. 68 ± 7%, WT vs. R6/2, P < 0.05). In WT mice, 
the increase in femoral relaxation between 12 and 16 weeks was due to enhanced NO dependent 
mechanisms. By 16 weeks of adult age, the R6/2 mouse developed overt endothelial dysfunction 
due to an inability to increase NO dependent vasodilation. The data add to the growing literature of 
non-neural manifestations of HD and implicate NO depletion as a key mechanism underlying the HD 
pathophysiology in the peripheral vasculature.
Huntington’s disease (HD) is a progressive, devastating and currently incurable neurodegenerative genetic disor-
der caused by a mutation in the HTT gene that codes for huntingtin1. The overt neurological signs and symptoms 
have previously directed investigators towards the nervous system as the primary site of pathology. Huntingtin, 
nevertheless, is expressed in many non-neuronal tissues although its extra-neuronal effects, including those in the 
cardiovascular system, are poorly characterised2–5. Whilst current evidence does not clearly support an increase 
in cardiovascular related mortality in patients with HD6, it is a common cause of death in patients with HD7 and 
many clinical studies have shown a significant shift in their autonomic cardiovascular control towards increased 
sympathetic dominance with reduced parasympathetic influences8–10. Interestingly, we and others have shown, in 
the R6/2 mouse model of HD, that significant cardiac dysfunction is already present at earlier stages of neurolog-
ical decline11–13. The R6/2 mouse has a smaller cardiac stroke volume, ejection fraction and cardiac output in vivo 
from 12 weeks of age, a stage where neurological signs are largely absent but the animals are failing to gain weight 
compared to WT mice13,14. When examined ex vivo, the R6/2 mouse is unable to generate the left ventricular 
pressure of its age matched WT counterpart at 16 weeks of age, an age by which the animals are clearly ‘sympto-
matic’11. Further, in vivo the R6/2 heart is unable to respond positively to β 1 adrenergic stimulation14.
Such overt derangements in cardiac function in the R6/2 mouse may be expected to be associated with periph-
eral vascular dysfunction. To date, however, only one study using the R6/1 mouse model of HD has examined this 
possibility15. In that study, Rahman et al. reported that there was no effect on dilator capacity in the aorta, although 
there was some evidence of vascular constrictor dysfunction in mesenteric and caudal vessels, which developed 
following the onset of neurological symptoms. No study has determined changes in vasodilator capacity in 
peripheral resistance vessels in HD, or whether any impairment is mediated via endothelium-dependent or inde-
pendent mechanisms. Here, we tested the hypothesis that the R6/2 mouse shows nitric oxide (NO)-dependent 
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endothelial dysfunction in peripheral resistance circulations, which pre-dates the neurological manifestations of 
HD. Given that HD patients and R6/2 mice display evidence of sympathetic autonomic dominance8–10, we further 
investigated femoral artery α 1-adrenergic constrictor function in addition to NO-dependent and independent 
dilator function in the R6/2 mouse at 12 and 16 weeks of age, corresponding to early symptomatic and established 
impaired neurological stages of the disease process, respectively16.
Methods
Animals. All procedures were performed in accordance with the UK Animals (Scientific Procedures) Act 
1986 and were overseen by the United Kingdom Home Office. Further local ethics committee approval was 
obtained from the University of Cambridge. Only male mice were studies to control for sex differences. Male mice 
were taken from a colony of R6/2 transgenic mice established in the Department of Pharmacology, University 
of Cambridge, and maintained by backcrossing onto CBA × C57BL6N F1 female mice17. Genotyping and CAG 
repeat length measurement were carried out by Laragen (Los Angeles, CA, USA) as described previously18. The 
transgenic mice used in this study had a mean CAG repeat length of 242 ± 1 (range 237–251). Mice were kept in 
home cages comprising single sex, single genotype groups of ten. All of the mice lived in an enhanced environ-
ment with increased amounts of bedding and nesting materials. Clean cages were provided twice weekly with 
grade 8/10-corncob bedding, and finely shredded paper for nesting. The mice were maintained on a 12:12 hour 
light/dark (LD) cycle, at a temperature of 21–23 °C and a humidity of 55 ± 10%. The mice had ad libitum access 
to water and dry laboratory food (RM3(E) rodent pellets, Special Diet Services, Witham, UK). In addition, once a 
day, a mash was prepared by soaking 100 g dry food in 230 ml water until the pellets were soft and fully expanded. 
The mash was placed on the cage floor, improving access to food and water for the R6/2 transgenic mice. This 
feeding regime has been shown previously to be beneficial19.
In vitro wire myography. Segments of femoral arteries were mounted on a wire myograph, as previously 
described in detail20,21. In brief, under a bifocal dissecting microscope (Brunel Microscopes Ltd., Wiltshire, UK), 
the first branch from the femoral artery of the left hind limb was excised and place in ice cold saline solution. 
The vessel was carefully cleaned of excess connective tissue and cut to a 2 mm long ring. Two 40 μ m diameter 
stainless steel wires were carefully threaded through the lumen of the femoral sections, maintaining the endothe-
lium intact. The wires were then placed between the mounting support jaws of a 4-chamber small-vessel wire 
myograph (Multi Wire Myograph System 610M; DMT, Aarhus, Denmark) containing warmed oxygenated Krebs 
buffer (NaCl 118.5 mM, Fisher Scientific; KCl 4.75 mM, Sigma; MgSO4.7H20 1.2 mM, Sigma; KH2PO4 1.2 mM, 
Sigma; NaHCO3 25.0 mM, Sigma; CaCl2 2.5 mM, Sigma; glucose 11.1 mM, Sigma, UK; bubbled continuously with 
95% O2/5% CO2 mix, 37 °C).
Force data from the myograph were recorded at 4 Hz (Labchart 6.0, Powerlab 8/30; AD Instruments, 
Chalgrove, UK), and each vessel was standardized to an optimal working tension of 100 mmHg22. Both vaso-
constrictor and vasodilator function was assessed in the vessels. All vessels were contracted with increasing con-
centrations of potassium chloride (KCl, 4.75–100 mM). Vasoconstrictor function to phenylephrine (PE: 10−9 to 
10−5 M; Sigma Aldrich, Poole, UK) and vasodilator responses to sodium nitroprusside (SNP: 10−9 to 10−4 M; 
Sigma Aldrich) and endothelium-dependent vasodilatation with the acetylcholine analogue methacholine (10−9 
to 10−4.5 M; Sigma Aldrich) were assessed. Vasoconstrictor responses to phenylephrine were normalised to the 
response of KCl at 40 mM for each vessel to standardise for any differences in muscle mass. Vasodilator responses 
with methacholine were assessed with no additive in the Krebs and separately with N(G)-nitro-L-arginine 
methyl ester (L-NAME, an endothelial nitric oxide synthase inhibitor; Sigma Aldrich, Poole, UK). All vasodi-
lator responses were assessed with the vessels pre-contracted with PE (10−5 M) at a stable plateau. Responses 
were recorded for 2 minutes after each dose, whereupon the next cumulative dose was given. Vessels were 
repeatedly washed with Kreb’s solution and allowed to equilibrate for at least 20 minutes between different 
concentration-response curves.
Analysis and statistics. Individual vessel responses were fitted to a Boltzmann sigmoidal (K+) or non-linear 
log (agonist) vs. response (PE, SNP, MetCh; GrpahPad Prism), as previously described In detail23. Maximal 
responses for each vessel and drug were taken from the curve fit value. Sensitivity was defined as the concentra-
tion of agonist required to elicit fifty percent of the maximal response expressed as either the EC50 (Excitatory 
concentration to achieve 50% maximal response) or pD2 (where pD2 = − log10 EC50)24. An index of total endothe-
lial relaxation (NO dependent + NO independent) was calculated in each vessel by calculating the area above the 
methacholine relaxation curve between 10−9 and 10−4 M as previously described21,23. An index of NO independ-
ent relaxation was calculated by the area above the methacholine relaxation curve in the presence of L-NAME 
and NO dependent relaxation was calculated as the difference between total and NO independent relaxation21,23. 
All data were compared statistically by Two-Way ANOVA followed by post hoc Bonferroni test where signifi-
cant effects of WT vs R6/2, 12 vs 16 weeks of age or an interaction were found. Significance was accepted when 
P < 0.05 (SigmaStat 2.0; SPSS Inc., Chicago, USA).
Results
Femoral artery vasodilator function. Both SNP and methacholine led to dose dependent vasodilation in 
femoral arteries from WT and R6/2 mice at 12 and 16 weeks of age in vessels pre-contracted with phenylephrine 
(Fig. 1, P < 0.05). There were no significant differences in the maximal response to SNP in any group, suggest-
ing no differences in vascular smooth muscle potential to vasodilate (Fig. 1). WT mice showed an increase in 
endothelial dependent relaxation in response to methacholine between 12 and 16 weeks of adulthood (Figs 1 
and 2). In contrast, R6/2 mice showed an increase in endothelial dependent relaxation already at 12 weeks and 
a significant decline by 16 weeks compared to WT mice at corresponding ages (Fig. 1). When NO dependent 
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and independent mechanisms underlying the endothelium-mediated relaxation were investigated, the increase 
in vasodilator capacity in the WT mice at 16 weeks was due to an increase in NO-dependent relaxation (Fig. 2). 
In contrast, this increase in NO-dependent endothelial mediated relaxation in the femoral resistance vessel with 
increasing age was not present in the R6/2 mouse (Fig. 2).
Figure 1. Femoral artery vasodilator function in the R6/2 mouse. Values are mean ± S.E.M. for the 
concentration-response curve maximal response and sensitivity to sodium nitroprusside (SNP) and 
methacholine in femoral arteries of 12 week old WT (○ , W12, n = 9), 12 week old R6/2 (● , R12, n = 9), 16 week 
old WT ( , W16, n = 9) and 16 week old R6/2 ( , R16, n = 7) mice. Concentration-response curves were 
analysed using an agonist-response best-fit line. The maximal relaxant response (%PEmax) was expressed as 
percentage of the contraction induced by phenylephrine and the vascular sensitivity was expressed as pD2  
(− logEC50). Different letters, a and b, represent significantly different responses between groups, P < 0.05. Two-
way ANOVA with post-hoc Bonferroni Test.
Figure 2. Relative contributions to endothelial dependent relaxation in the R6/2 mouse. The data show the 
area above the relaxation curve in response to methacholine. The total bar represents total vasodilator capacity. 
NO independent relaxation is the area above the curve in the presence of the NOS inhibitor L-NAME and NO 
dependent is the difference between total vasodilator capacity and NO independent relaxation. Experiments 
performed in femoral arteries of 12 week old WT (W12, n = 8), 12 week old R6/2 (R12, n = 6), 16 week old WT 
(W16, n = 8) and 16 week old R6/2 (R16, n = 5) mice. Different letters, a and b, represent significantly different 
responses between groups, P < 0.05. Two-way ANOVA with post-hoc Bonferroni Test.
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Femoral artery vasoconstrictor function. At both 12 and 16 weeks of age, application of KCl and PE led 
to dose dependent increases in femoral arterial tension in both WT and R6/2 mice (Fig. 3). WT mice showed a 
decrease in the maximal vasoconstrictor response to PE with advancing age from 12 to 16 weeks. In contrast, the 
R6/2 mouse showed impaired maximal constrictor responses to PE already at 12 weeks compared to WT, which 
was not worsened further by 16 weeks (Fig. 3). There were no differences in the maximal response or sensitivity 
to KCl.
Discussion
The striking neurological manifestations of HD have led investigators to focus on the nervous system in search 
of the underlying pathology and management of this disorder1. However huntingtin, the mutated protein, is 
expressed extensively at many extra-neuronal sites including the heart and circulatory system3. Here, we show 
that endothelial function is significantly altered in peripheral resistance arteries of the R6/2 mouse from 12 weeks 
of age and grossly impaired by 16 weeks. In contrast to WT mice, which showed an increase from 12 to 16 weeks 
of age in endothelial-mediated relaxation via increased NO-dependent mechanisms, the R6/2 mouse failed to 
recruit NO-dependent pathways and increase relaxation from 12 to 16 weeks of age. Furthermore, at 12 weeks of 
age, before the onset of overt neurological signs in this model, the R6/2 mice displayed significant enhancement 
of endothelial-dependent dilation and impaired α 1 adrenergic vasoconstrictor responses. Collectively, the data 
support the hypothesis tested and show for the first time significant peripheral vascular endothelial dysfunction 
due to impaired NO-dependent mechanisms in a mouse model of HD. We also provide evidence for the periph-
eral vascular dilator and constrictor dysfunction preceding the onset of overt neurological symptoms.
Several mechanisms may be involved in triggering dysfunction in peripheral resistance circulations. In the 
present study, our data suggest that in the R6/2 mouse model of HD alterations in endothelial function and in NO 
biology may contribute to the pathophysiological decline. It is now understood that the cellular oxidant milieu is 
an important modulator of peripheral vascular resistance25. In resistance vessels, the balance between superoxide 
(.O2−) and NO has important effects on endothelial function, both under physiological regulation and in disease 
pathophysiology. Under physiological conditions, the ratio of vascular NO:.O2− is an important determinant of 
vascular tone. Therefore, during conditions in which NO production outweighs ·O2− production, the increase 
Figure 3. Femoral artery vasoconstrictor function in the R6/2 mouse. Values are mean ± S.E.M. for the 
concentration-response curve maximal response and sensitivity to potassium chloride (KCl) and phenylephrine 
in femoral arteries of 12 week old WT (○ , W12, n = 9), 12 week old R6/2 (● , R12, n = 9), 16 week old WT  
( , W16, n = 9) and 16 week old R6/2 ( , R16, n = 7) mice. Concentration-response curves were analysed 
using an agonist-response best-fit line. The maximal contractile response and sensitivity to each drug are shown. 
Different letters, a and b, represent significantly different responses between groups, P < 0.05. Two-way ANOVA 
with post-hoc Bonferroni Test.
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in the NO:.O2− ratio promotes vasodilation25,26. When vascular ·O2− production outweighs NO, this leads to 
vascular constriction and an increase in peripheral vascular resistance25,26. Under pathological conditions, excess 
generation of reactive oxygen species and oxidative stress may therefore decrease NO bioavailability and promote 
endothelial dysfunction. Interestingly, it is already known that the huntingtin protein promotes oxidative stress27. 
Indeed, reactive oxygen species mediated mitochondrial DNA damage28, general protein nitrosylation27 and lipid 
peroxidation27,29 are all found in HD. Further, mitochondrial dysfunction has been strongly associated with a rise 
in oxidative stress in HD27,30. Specifically the R6/2 mouse displays dysfunction of voltage-dependent anion chan-
nel 131, which is a key component of the mitochondrial permeability transition pore and a regulator of superoxide 
anion leakage from mitochondria30,32. Collectively, past and present data therefore suggest impaired NO signal-
ling as one mechanism underlying the inability of the R6/2 mouse to increase femoral artery vasodilation from 12 
to 16 weeks of adult age. The enhanced femoral artery dilation at 12 weeks of age in the R6/2 mouse may represent 
a compensatory response to impaired NO bioavailability, an adaptive response which is later decompensated as 
NO-dependent vasodilation fails at 16 weeks.
Additional data in the present study show no alteration in peripheral vasoconstrictor function in response to 
potassium between the groups but a markedly impaired femoral artery α 1-mediated constrictor response already 
at 12 weeks of life in the R6/2 mouse, akin to that measured in the WT mouse much later at 16 weeks of age. It is 
known that HD patients show a sympathetically dominated autonomic nervous system phenotype8–10. As well 
as driving sympathetically dominant patterns of heart rate variability and structural and functional abnormal-
ities in the heart, it is possible that the autonomic sympathetic outflow to the vasculature is also enhanced in 
the R6/2 mouse. In the R6/2 mouse, it has been suggested that the cardiomyopathy is caused by altered central 
autonomic pathways, since neither mutant huntingtin aggregates nor a HD-specific transcriptional dysregula-
tion was identified in cardiac tissue, even at the end stage of disease13. While aggregates of mutant huntingtin 
are a hallmark of HD brain, their presence (or lack thereof) does not always correlate with pathological cellular 
pathology. Therefore, it is possible that cell autonomous pathology in cardiac tissue is present. This remains to be 
investigated directly. Nevertheless, alterations in the metabolic and endocrine milieu which impact on vascular 
function are established in HD. For example, plasma cortisol levels are raised in both the R6/1 and R6/2 mouse 
model of HD, an effect which would also contribute to enhance α 1-adrenergic receptor mediated peripheral 
vasoconstriction15,33,34. In the R6/1 model of HD, plasma noradrenaline levels are reported to be 4–5x higher than 
WT animals at 7 months of age, when the R6/1 animal shows advanced HD-like phenotype35. Sustained increases 
in sympathetic nervous system activity and in circulating catecholamine and glucocorticoids are strongly asso-
ciated with endothelial dysfunction and cardiovascular disease in general36. Therefore, the accelerated loss of the 
α 1-adrenergic receptor mediated reactivity in peripheral resistance vessels of the R6/1 mouse may represent an 
adaptive response, down-regulating α 1-adrenoreceptor responsiveness to an increased sympathetic drive, which 
is exacerbated by increased circulating plasma glucocorticoid concentrations. Interestingly, in human patients 
with Huntington’s disease there appear to be no substantial differences in hypothalamic-pituitary-adrenal axis 
control37.
Finally, changes in sympathetic stimulation combined with expression of the huntingtin protein may lead to 
structural alterations in resistance vessels. Defects have been reported in neurovascular tissue from humans with 
HD and in mouse models at the level of the blood brain barrier38, although in the R6/1 mouse there is no appar-
ent peripheral vascular remodelling in mesenteric or caudal arteries15. In support of this, in the present study, 
responses to potassium chloride, which reflect a global measure of vascular smooth muscle structure, mass and 
function, were not altered in the R6/2 compared to WT mouse.
Translational perspective. Clinical studies show clearly that cardiovascular dysfunction is present in HD. 
Furthermore, the recent body of evidence in animal models of HD confirms that the systemic over-expression 
of huntingtin leads to premature cardiac and vascular dysfunction. Despite this, in clinical practice, HD is still 
perceived almost exclusively as a neurological disorder due to the overt neurological manifestations, with little or 
no clinical appreciation for extra-neuronal sites of expression of the disease. Using an established mouse model of 
HD, here we show that endothelial NO-dependent function is markedly impaired in the peripheral vasculature. 
Collectively, past and present data therefore support increasing attention to the monitoring of the cardiovascu-
lar system in patients with HD. In particular, investigation of whether treatment with drugs that enhance NO 
bioavailability already in common clinical use, such as statins, may protect peripheral vascular function in HD 
patients is warranted.
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